Literature DB >> 20362990

Challenges associated with hypertensive disease during pregnancy in low-income countries.

Kwabena A Danso1, Henry S Opare-Addo.   

Abstract

OBJECTIVE: To assess the challenges associated with the diagnosis, management, and prevention of hypertensive disease during pregnancy in low-income countries, following the success of the Magpie Trial.
METHODS: Descriptive review of the literature from 1990 to 2009 on the diagnosis, management, and prevention of hypertensive disease in pregnancy.
RESULTS: In the absence of credible measures to predict and prevent hypertension in pregnancy, diagnosis and treatment remain the only viable options, although they are still associated with important challenges in low-income countries. Despite the presence of high-quality evidence that magnesium sulfate is safe and effective at preventing and treating eclampsia, its use is extremely limited in many low-income countries.
CONCLUSION: There is a need for cheap and reliable tools with which to address the diagnostic, preventive, and management challenges associated with hypertensive disease during pregnancy in low-income countries. It is recommended that such countries incorporate magnesium sulfate protocols into their national health and/or practice policies. Copyright (c) 2010 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362990     DOI: 10.1016/j.ijgo.2010.01.026

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  9 in total

1.  Monitoring severe pre-eclampsia and eclampsia treatment in resource poor countries: skilled birth attendant perception of a new treatment and monitoring chart (LIVKAN chart).

Authors:  Charles A Ameh; Christine I Ekechi; Jamilu Tukur
Journal:  Matern Child Health J       Date:  2012-07

2.  Eclapmsia: The Major Cause of Maternal Mortality in Eastern India.

Authors:  Ratan Das; Saumya Biswas
Journal:  Ethiop J Health Sci       Date:  2015-04

3.  Knowledge, Perception and Management of Pre-eclampsia among Health Care Providers in a Maternity Hospital.

Authors:  Titilayo Olaoye; Oyewole O Oyerinde; Oluwatoyin J Elebuji; Oluwapelumi Ologun
Journal:  Int J MCH AIDS       Date:  2019-08-08

4.  Role of Palm Oil Vitamin E in Preventing Pre-eclampsia: A Secondary Analysis of a Randomized Clinical Trial Following ISSHP Reclassification.

Authors:  Nurul Afzan Aminuddin; Rosnah Sutan; Zaleha Abdullah Mahdy
Journal:  Front Med (Lausanne)       Date:  2021-01-21

5.  Improved quality of management of eclampsia patients through criteria based audit at Muhimbili National Hospital, Dar es Salaam, Tanzania. Bridging the quality gap.

Authors:  Hussein Lesio Kidanto; Peter Wangwe; Charles D Kilewo; Lennarth Nystrom; Gunnila Lindmark
Journal:  BMC Pregnancy Childbirth       Date:  2012-11-21       Impact factor: 3.007

6.  Interbirth interval and history of previous preeclampsia: a case-control study among multiparous women.

Authors:  Arusyak Harutyunyan; Haroutune Armenian; Varduhi Petrosyan
Journal:  BMC Pregnancy Childbirth       Date:  2013-12-27       Impact factor: 3.007

Review 7.  Prevention of Hypertensive Disorders of Pregnancy: a Novel Application of the Polypill Concept.

Authors:  J L Browne; K Klipstein-Grobusch; A Franx; D E Grobbee
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

8.  Maternal and perinatal outcomes among women with hypertensive disorders in pregnancy in Kumasi, Ghana.

Authors:  Edward T Dassah; Eunice Kusi-Mensah; Emmanuel S K Morhe; Alexander T Odoi
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

9.  Hypertensive Disorders of Pregnancy and Medication Use in the 2015 Pelotas (Brazil) Birth Cohort Study.

Authors:  Lisiane Freitas Leal; Sonia Marzia Grandi; Vanessa Iribarrem Avena Miranda; Tatiane da Silva Dal Pizzol; Robert William Platt; Mariângela Freitas da Silveira; Andréa Dâmaso Bertoldi
Journal:  Int J Environ Res Public Health       Date:  2020-11-18       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.